Document Detail

Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
MedLine Citation:
PMID:  19784898     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A common G to T transition in codon 34 with the subsequent valine with leucine replacement in the factor (F) XIII A-subunit affects fibrin formation and stabilisation in vitro. Data on the effects of Leu34 allele on cardiovascular thromboembolic events in vivo are conflicting. AIM: We investigated whether FXIII Val34Leu polymorphism is potent enough to affect fibrin clot properties in patients with advanced coronary artery disease (CAD). METHODS: We studied 113 patients, aged 62.8 +/- 6.1 years, who were scheduled for elective isolated coronary artery bypass grafting surgery (CABG). Patients were compared with 98 healthy age-matched controls. Ex vivo fibrin clot permeability and lysis time (t5oo/o) were determined in citrated plasma. RESULTS: Patients scheduled for CABG had lower clot permeability (9.14 + 1.64 vs. 10.02 + 1.12 x 10(-9) cm2; p = 0.0002) and longer t50%, (8.45 +/- 1.94 vs. 7.63 +/- 1.24 min; p < 0.0001) than controls. The Leu34 carriers, i.e. 9 (8%) Leu34Leu homozygous and 23 (20%) Val34Leu heterozygous subjects, had lower permeability by 23% in the CAD group compared with 81 (72%) patients with Val34Val genotype. A similar intergroup difference was observed for t50%, which was longer in Leu34 carriers (p < 0.0001). The FXIII Leu34 allele frequency in the control group was similar as well as the impact of Leu34 allele on fibrin properties. The effect of FXIII Leu34 allele on permeability and t50%, was not affected by homocysteine, C-reactive protein and fibrinogen levels in CAD patients and controls. CONCLUSIONS: Like in healthy subjects, in patients scheduled for CABG, the FXIII Leu34 allele is associated with decreased fibrin clot permeability and efficiency of lysis.
Ewa Stepień; Dariusz Plicner; Bogusław Kapelak; Ewa Wypasek; Jerzy Sadowski; Anetta Undas
Related Documents :
20304868 - Levels of scd40 ligand in chronic and acute coronary syndromes and its relation to angi...
1818428 - Use of doppler's echocardiography for the examination of nitromint spray in coronary di...
17056318 - Effectiveness of prehospital wireless transmission of electrocardiograms to a cardiolog...
18586758 - Serum selenium and glutathione peroxidase concentrations in iranian patients with angio...
11779898 - Hemodynamic and metabolic changes in transient ischemic attack patients: a magnetic res...
18842368 - Magnetoencephalography using total intravenous anesthesia in pediatric patients with in...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kardiologia polska     Volume:  67     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-12-29     Completed Date:  2010-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  947-55     Citation Subset:  IM    
Department of Cardiac Surgery, Anesthesiology and Experimental Cardiology, Institute of Cardiology, Jagiellonian University Collegium Medicum, Krakow, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
C-Reactive Protein / metabolism
Case-Control Studies
Coronary Artery Bypass
Coronary Artery Disease / blood,  genetics*,  surgery
Factor XIII / genetics*
Fibrin / genetics*,  metabolism
Fibrinolysis / genetics*
Homocysteine / blood
Middle Aged
Polymorphism, Genetic*
Risk Assessment
Reg. No./Substance:
454-28-4/Homocysteine; 9001-31-4/Fibrin; 9007-41-4/C-Reactive Protein; 9013-56-3/Factor XIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  POL-TAVI First - Polish report on transcatheter aortic valve implantation (TAVI) of Edwards-Sapien p...
Next Document:  Sutureless aortic valve bioprothesis '3F/ATS Enable' - 4.5 years of a single-centre experience.